Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Medtronic
AstraZeneca
Colorcon
US Department of Justice
Covington
Harvard Business School
McKesson
Chubb

Generated: January 19, 2018

DrugPatentWatch Database Preview

Teva Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?

TEVA PHARMS has two hundred and sixty-six approved drugs.

There are fifteen US patents protecting TEVA PHARMS drugs and there have been two Paragraph IV challenges on TEVA PHARMS drugs in the past three years. There are thirty-four tentative approvals on TEVA PHARMS drugs.

There are ninety-eight patent family members on TEVA PHARMS drugs in thirty-four countries and three hundred and eighty-nine supplementary protection certificates in thirteen countries.

Summary for Teva Pharms
International Patents:98
US Patents:15
Tradenames:221
Ingredients:214
NDAs:266

Drugs and US Patents for Teva Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms CEFUROXIME SODIUM cefuroxime sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 064192-001 Apr 16, 1998 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa RISEDRONATE SODIUM risedronate sodium TABLET;ORAL 077132-002 Oct 5, 2007 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms CEFPROZIL cefprozil FOR SUSPENSION;ORAL 065236-001 Dec 8, 2005 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms FLUVASTATIN SODIUM fluvastatin sodium CAPSULE;ORAL 078407-002 Jun 12, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa ATOMOXETINE HYDROCHLORIDE atomoxetine hydrochloride CAPSULE;ORAL 079022-001 May 30, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa NOREPINEPHRINE BITARTRATE norepinephrine bitartrate INJECTABLE;INJECTION 040455-001 Mar 3, 2003 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa OCTREOTIDE ACETATE octreotide acetate INJECTABLE;INJECTION 075957-002 Oct 3, 2005 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms PRAZOSIN HYDROCHLORIDE prazosin hydrochloride CAPSULE;ORAL 071745-003 Sep 12, 1988 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa ETOPOSIDE etoposide INJECTABLE;INJECTION 074529-001 Jul 24, 1996 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Teva Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 10/26/2016
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 6/3/2015
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2/26/2014
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 1/29/2014
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 8/11/2008
Premature patent expirations for TEVA PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Teva Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,842,687 Cephalotaxane derivatives and their processes of preparation and purification ➤ Subscribe
8,877,245 Modified release dosage forms of skeletal muscle relaxants ➤ Subscribe
6,613,900 Cephalotaxane derivatives and process for their preparation ➤ Subscribe
7,169,774 Cephalotaxane derivatives and their processes of preparation and purification ➤ Subscribe
6,831,180 Cephalotaxane derivatives and process for their preparation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Teva Pharms Drugs

Supplementary Protection Certificates for Teva Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0044 Netherlands ➤ Subscribe PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001
01C/021 Belgium ➤ Subscribe PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610
C/GB99/024 United Kingdom ➤ Subscribe PRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312
/1998 Austria ➤ Subscribe PRODUCT NAME: ''IRBESARTAN'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE; NAT. REGISTRATION NO/DATE: EU/1/97/046/001 - EU/1/97/046/009 19970827; FIRST REGISTRATION: LI 5425002 19970815
/2005 Austria ➤ Subscribe PRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217
2016000104 Germany ➤ Subscribe PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
0885 Netherlands ➤ Subscribe PRODUCT NAME: ONIVYDE - IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018
C0030 Belgium ➤ Subscribe PRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327
2012 00021 Denmark ➤ Subscribe PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ET FARMACEUTISK ACCEPTABELT ADDITIONSSALT AF RILPIVIRIN, HERUNDER HYDROCHLORID ADDITIONSSALTET AF RILPIVIRIN, OG TENOFOVIR, NAVNLIG TENOFOVIRDISOPROXILFUMARAT; REG. NO/DATE: EU/1/11/737/001-002 20111128
0768 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE VAN RILPIVIRINE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN DIE BESCHERMD WORDT DOOR HET BASISOCTROOI, ZOALS EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN RILPIVIRINE, WAARONDER HET HYDROCHLORIDEZOUT VAN RILPIVIRINE. TENOFOVIR, IN HET BIJZONDER TENOFOVIRDISOPROXILFUMARAAT. EN EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Chinese Patent Office
Merck
Healthtrust
Federal Trade Commission
Colorcon
McKinsey
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot